Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Investigation of the Anxiolytic Effects of Naringenin, a Component of Mentha Aquatica, in the Male Sprague-Dawley Rat

Anderson, Wesley BSN, EMBA, MMAS, CCRN, ANC; Barrows, Mark BSN, ANC; Lopez, Fernando BSN, CCRN, ANC; Rogers, Sara BSN, CCRN, ANC; Ortiz-Coffie, Adriana BSN, MHA, CNOR, ANC; Norman, David BSN, BS, CCRN, ANC; Hodges, Jonathan BSN, ANC; McDonald, Keith BSN, ANC; Barnes, Devon BSN, ANC; McCall, Suzanne ALAT; Don, Johnson Arthur RN, PhD; Ceremuga, Thomas E. CRNA, PhD

doi: 10.1097/HNP.0b013e31823c003a

This was a prospective, randomized, between-subjects experimental study to investigate the anxiolytic effects of naringenin, a component of mentha aquatica, and its potential interaction with the benzodiazepine binding site on the γ-aminobutyric acid (GABAA) receptor in the rat. Fifty-five rats were assigned to one of 5 groups with 11 rats per group: control, naringenin, midazolam, midazolam with naringenin, and flumazenil with naringenin. The elevated plus maze measured the behavioral components of anxiety and motor movements. Our data suggest that naringenin does not produce anxiolysis by modulation of the GABAA receptor; however, the findings indicate that naringenin decreases motor movements (P < .05).

US Army Graduate Program in Anesthesia Nursing, US Army.

Correspondence: Thomas E. Ceremuga, CRNA, PhD, AMEDDC&S Nursing Science, 3490 Forage Rd, Ste 112, Fort Sam Houston, TX 78234 (

The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the US Government.

The authors are grateful for the generous funding by the American Association of Nurse Anesthetists (AANA) Foundation and Brooke Army Medical Center Department of Clinical Investigation, which supported this study.

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

© 2012 Lippincott Williams & Wilkins, Inc.